ANAGRELIDE Drug Patent Profile

Which patents cover Anagrelide, and when can generic versions of Anagrelide launch?

Anagrelide is a drug marketed by Barr Labs, Chartwell Rx, Cipla, Impax Labs, Novitium Pharma, Rising, Roxane, Torrent, and Watson Labs. and is included in nine NDAs.

The generic ingredient in ANAGRELIDE is anagrelide hydrochloride. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the anagrelide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Anagrelide

A generic version of ANAGRELIDE was approved as anagrelide hydrochloride by CIPLA on April 18^th, 2005.

Summary for ANAGRELIDE

US Patents:	0
Applicants:	9
NDAs:	9
DailyMed Link:	ANAGRELIDE at DailyMed

US Patents and Regulatory Information for ANAGRELIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr Labs	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076530-001	Apr 18, 2005		DISCN	No	No
Watson Labs	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076417-002	Apr 18, 2005		DISCN	No	No
Impax Labs	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076910-001	Apr 18, 2005	AB	RX	No	No
Chartwell Rx	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076683-002	Apr 18, 2005		DISCN	No	No
Rising	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	077613-002	Jun 27, 2006		DISCN	No	No
Impax Labs	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076910-002	Apr 18, 2005	AB	RX	No	No
Torrent	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	209151-002	Jun 30, 2017	AB	RX	No	No